摘要
目的：探讨雌激素受体（ER）拮抗剂ICI182780（Faslodex）对17β-雌二醇（E2）作用下ER阳性的Ishikawa细胞和ER低表达的HEC-1A子宫内膜癌细胞系细胞的增殖、凋亡和细胞周期的影响，初步探讨ICI182780治疗子宫内膜癌的可行性。方法：应用四甲基亚唑蓝（MTT）法、流式细胞技术观察ICI182780对E2作用下的子宫内膜癌细胞增殖、凋亡和细胞周期的影响。结果：随着E2浓度的增加和作用时间的延长，子宫内膜癌细胞在570nm处的光密度值增大，Ishikawa细胞G0-G1期的比例减少，S期的比例增多，HEC-1A细胞各期的比例变化不显著。随着ICI182780的浓度增加，ICI182780可以使E2作用下Ishikawa细胞的光密度值逐渐下降至基础状态水平，并且使其发生细胞凋亡，表现为早期凋亡细胞增多，使细胞G0～G1期的比例升高，S期的比例下降；HEC-1A细胞的上述变化不显著。结论：ICI182780可以抑制E2对Ishikawa细胞的促增殖作用，促使其发生凋亡，同时也使细胞周期停滞在G1期；ICI182780对HEC-1A细胞的增殖、凋亡和细胞周期无明显影响。ICI182780有可能用于ER阳性子宫内膜癌的治疗。
Objective： To observe the influence of estrogen receptor, ICI182780, on proleferation, cell cycle progression and apoptosis in estrogen receptor （ER）-positive and ER-poor endometrial carcinoma cells and to explore the possible preliminary value of ICI182780 treating endometrial carcinoma. Methods： The effects of ICI182780 on proliferation, apoptosis and cell cycle distrubution of endometrial cancer cells costimulated with 10^-6 of mol/L E2 was detected by monotetrazolium （MTT） assay and fluorescence-activated cell sorting technique. Results ： With increased concentrations of E2, values of OD 570 nm for endometrial cancers increased gradually especially in Ishikawa. Cell cycle distribution analysis revealed that percentage of Ishikawa cells at G0-G1 phase decreased and percentage at S phase increased significantly, whereas that of HEC-1A cells didn＇ t show significant alteration. In cotreatment of endometrial cancer cells with ICI182780, values of OD 570 nm and numbers of apoptotic cells of Ishikawa cells decreased to basal levels, G0-G1 phase proportion increased, percentage of S phase increased in a timeor time-dependent manner. But there was no such alteration in HEC-1A cells. Conclusion： The specific ER antagonist, ICI182780, can inhibit Ishikawa cell propagation induced by E2, make cells apoptosis and block Ishikawa cells at the GI/S transition. Therefore, ICI182780 may be a valid approach to treat ER-positive endometrial carcinoma.
出处
《北京大学学报（医学版）》
CAS
CSCD
北大核心
2006年第5期470-474,共5页
Journal of Peking University:Health Sciences
